Findings
Lack of regulatory guidance on validating precision and reliability of DHT data.
Challenges in managing large, complex datasets without appropriate processing.
Insufficient integration of DHTs into existing clinical trial standards.

Recommendations
Develop a metadata set to improve data interpretability and exchangeability.
Encourage standard development organizations to extend existing standards for DHTs.
Ensure that none of the proposed metadata is compulsory, allowing flexibility based on application and resources.

Regulatory Considerations
Meet additional regulatory standards for medical devices.
Utilize guides like the FDA’s Clinical Trials Transformation Initiative for data capture.
Align metadata standards with regulatory requirements to facilitate approval.